

PIERLUIGI PARACCHI

PIERLUIGI.PARACCHI@GENENTA.COM



CAREER OVERVIEW

CO-FOUNDER AND CEO

2014 – PRESENT

Genenta Science, Milano (Italy)

Genenta (NASDAQ: GNTA) is a clinical stage immune oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro environment. Genenta's lead product candidate, Temferon, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.

MODERATOR OF THE WORKING TABLE FOR THE INTERNATIONALIZATION OF BIOTECHNOLOGY SECTOR

2024 – PRESENT

Ministero degli Affari Esteri e della Cooperazione Internazionale

The establishment of the round table, which is called upon to formulate strategies and recommendations on the internationalisation of players active in the field of biotechnology in order to strengthen the entire national sector, “reflects the attention that the Italian government attaches to the international development of innovative supply chains and emerging technologies, within the framework of Growth Diplomacy”, according to the vice premier and Foreign Minister Antonio Tajani.

The table will be attended by representatives of institutions, research centres, companies, trade associations and the financial world. Among others, as moderator, Pierluigi Paracchi, CEO of Genenta and member of the Executive Committee of Federchimica-Assobiotech; Pierluigi Petrone, Vice President of Farmaindustria; Giovanni Caforio, Executive Chairman of Bristol Myers Squibb; Maria Cristina Porta, General Director of the ENEA Tech and Biomedical Foundation; Giuseppe Gigli, Director of the CNR-Nanotec Institute of Nanotechnology; Rino Rappuoli, Scientific Director of Fondazione Biotecnopolo di Siena; Gianmario Verona, President of Human Technopole. Representatives of the Italian Ministry of Enterprises and Made in Italy, the Italian Ministry of University and Research and the ICE Agency will also be attending.

CO-FOUNDER AND BOARD MEMBER

2017 – PRESENT

Altheia Science Milano (Italy)/ New York (NY)

Altheia Science is a pioneering start-up founded by two world renowned Italian scientists, Prof. Alessandra Biffi, MD and Prof. Paolo Fiorina, MD, PhD, together with AurorA-TT. Altheia Science's pipeline exploits pioneering therapeutic tools for autoimmune diseases and cancer. The modulation of PD-L1 expression at the molecular and protein level is key to devise advanced treatments. This can be achieved by first-in-class molecules controlling the PD-L1 pathway and/or by lentiviral vector-based engineering of patients' hematopoietic stem cells. Altheia Science's approach intends to drastically modify the natural history of diseases with high clinical impact in autoimmunity and cancer by modulating PD-L1 expression, achieving tangible and durable benefit for each patient.

CHAIRMAN OF THE BOARD

2020 – PRESENT

Lipogems International Medical device for processing adipose tissue.

CO-FOUNDER AND BOARD MEMBER

2020 – PRESENT

AurorA Science AurorA Science is a biotech investment company integrating an Innovative financial and industrial approach in the research and development challenge. The company is focused on independent and entrepreneurial biotech start-ups with high therapeutic potential.
AurorA Science is the result of the partnership between the technology transfer company AurorA-TT and two strategic industrial partners and investors, namely Rottapharm Biotech and Italfarmaco, partners that share in-house R&D facilities and expertise to support the development of portfolio companies and create the ideal conditions for partnering with bio-pharma companies.

CO-FONUDER AND VENTURE PARTNER

2017 – PRESENT

AurorA-TT Milano (Italy) AurorA-TT is a Technology Transfer Investment Company established in 2017 based in Milan, Italy. We identify promising scientific breakthroughs from academia and research centers in Italy and partner with academia, research institutions and biotech companies based globally.
We invest in early projects to bridge the gap between basic research and industrial drug development with industrial discipline.

CO-FOUNDER & INVESTMENT COMMITTEE MEMBER - VC FUND OF FUNDS

2007 – PRESENT

Axon Partners Group Madrid area (Spain) Aurora is a leading tech Fund of Funds platform able to cover global opportunities in multi sector strategies such as ICT, Life Sciences and Deep Tech sectors in the Venture Capital space, combining primary investments, co- investments and secondary transactions.

Axon Partners Group (Axon) is a global Investment, Alternative Asset Manager and Advisory firm with presence and experience worldwide. Axon's reputation for excellence is well known among investors and clients all around the world. Axon was founded by entrepreneurs with extensive financial and business development experience. Axon has grown to create a team of more than 80 experts in our offices in Madrid, Istanbul, Mexico City, Bogotá, Riyadh and Seville.

STEERING COMMITTEE MEMBER AND EXECUTIVE COMMITTEE MEMBER

2016 – PRESENT

Assobiotec Assobiotec, the Italian Association for the Development of Biotechnology, was born to foster, support and defend the development of biotechnology in all its various application fields.
Set up in 1986 within the Italian Federation of the Chemical Industry (Federchimica), Assobiotec represents companies and science & technology parks operating in Italy and involved in several sectors of life sciences.

COORDINATOR - BOWLING GREEN BULL INITIATIVE

2022 – PRESENT

American Chamber of Commerce in Italy Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and expansion in their interactions with U.S. financial markets and investors.
BGB will function as a meeting and discussion community for entrepreneurs and managers of listed companies or those aiming to list in the U.S., as well as facilitators such as banks, advisors and lawyers who deal with the U.S. stock markets.

The initiative, promoted by the American Chamber of Commerce in Italy (AmCham Italy) and Genenta Science SpA (Nasdaq: GNTA), currently includes Bank of America (NYSE: BAC), Brunswick Group, Cleary Gottlieb Steen & Hamilton LLP, Docebo (Nasdaq: DCBO), D-Orbit, Equita Capital SGR, Kairos Partners SGR, Nasdaq (Nasdaq: NDAQ), Petrone Group and other Italian companies listed on U.S. stock markets.

MEMBER OF THE BOARD

2018 – PRESENT

InnovUp - Italian Innovation & Startup Ecosystem Milano (Italy) Italia Startup is the non-profit association that represents, supports, and gives voice to the Italian innovation ecosystem. Founded in 2012, in response to the government's call to the Italian innovation actors, the association brings together among others entrepreneurs, incubators, investors, startupper, public entities, and private companies.

BOARD MEMBER

2020 – PRESENT

Assolombarda Chemical Group - Life Sciences Unit

IAB MEMBER

2015 – PRESENT

Italian Angels for Biotech IAB is an association made by a group of people with significant experience in Life Sciences. IAB goal is to identify and nurture top talent entrepreneurs in the Life Sciences sector. IAB leads equity investments to help ideas and start-ups to reach key objectives. Members include successful entrepreneurs and investors, prominent executives, advisors, physicians and scientists. Most IAB members have been also founders and/or senior executives in companies within the healthcare space. www.ItalianAB.it

CONTRIBUTOR

2013 – PRESENT

EconomyUp "Three-Comma Club" Blog

PARTNER

2013 – PRESENT

Medixea Capital Milano (Italy) Medixea Capital handles the investments of Principia Fund, a Venture Capital fund launched by Quantica SGR: EOS - Ethical Oncology Science and Banzai Group are part of the portfolio.

Consultant of Sofinnova Capital VII (2011-2014), a 240M€ Venture Capital Fund specialized in Series A investments in Life Science (biotech, pharma, medical devices and industrial biotech).

Sell Side Advisor to Simple Agency (2011-2013) in the acquisition by Dentsu- Aegis Group (digital marketing services provider).
 Sell Side Advisor to Performedia (2013-2014) in the acquisition by Digitouch Group (digital marketing provider).
 Buy Side Advisor to Digital360 (2014-2015).

Mentorship: (2011-14) StartUp Program Politecnico Milano; (2014) StartUP SuperSummit - Tiscali; (2014) Master MCA SISSA Trieste; (2014) Stati Generali Salute, Italian Ministry of Health; (2014) ItaliaCamp #ValorePaese, Reggio Emilia; (2104) FareteTalk, Unindustria Bologna; (2014) TEDxBologna.

Promoter #startupNOTax (march '14).

Contributor (2013-2015) at www.EconomyUp.it

Member of the Research and Innovation Commission - Italian Ministry of Health (2014-2015).

MEMBER OF THE EVALUATION COMMISSION

2015 – PRESENT

Università Cattolica del Sacro Cuore - ConLab Milano (Italy) ConLab is the Catholic University coworking space.

LIFE SCIENCES TECHNICAL GROUP MEMBER		2016 – 2020
Confindustria	Confindustria is the main association representing manufacturing and service companies in Italy, with a voluntary membership of more than 150,000 companies of all sizes, employing a total of 5,434,352 people.	
START-UP DELEGATE		2016 – 2020
Cluster Life Science Lombardia	The cluster aims to favor the aggregation of resources. We bring together industry, academia and clinical community to support the advance of life sciences in Lombardy.	
BOARD DIRECTOR		2014 – 2015
Performedia S.r.l. Milano (Italy)	<p>Performedia has great experience in Digital ADV oriented to results. Performedia works to optimize every detail of the Digital Media Mix (Credibility, Reputation, Product) contextualizing it in the market's scenario (Competitors) and taking the flows of Web interactions into consideration.</p> <p>Performedia is part of Digitouch Group, the independent leader in digital marketing in Italy (listed on AIM).</p>	
SELL SIDE ADVISOR		2013 – 2014
Performedia S.r.l. Milano (Italy)	<p>Performedia has great experience in Digital ADV oriented to results. Performedia works to optimize every detail of the Digital Media Mix (Credibility, Reputation, Product) contextualizing it in the market's scenario (Competitors) and taking the flows of Web interactions into consideration.</p> <p>September 9, 2014. Digitouch announced the acquisition of Performedia. Digitouch is the Italian independent leader in media and digital communications.</p>	
BUY SIDE ADVISOR		2014 – 2015
Digital360 Milano (Italy)	Digital360 is an Italian leader in B2B editorial contents, marketing and communication services, lead generation, events and webinars, advisory, advocacy e coaching, in the Digital Transformation and Entrepreneurial Innovation.	
VENTURE CONSULTANT		2011 – 2014
Sofinnova Partners	Sofinnova Partners is an independent venture capital firm based in Paris, France. For 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside Europe's key entrepreneurs in the Life Sciences industry. With €1.3 billion of funds under management, Sofinnova Partners has created market leaders with its experienced team and hands-on approach in building portfolio companies through to exit.	
INVESTOR AND BOARD DIRECTOR		2008 – 2013
EOS Ethical Oncology Science	Pharma Company specialized in oncology, drug development. Shareholders as Investors: Quantica SGR (IT), Sofinnova Partners (F) and Aescap Ventures (NL). Industrial Partner: Servier, the first French independent pharmaceutical group (EU rights - 2012: upfront 45M€ + milestones and royalties). EOS was acquired in November 2013: 200M\$ upfront + 220M\$ milestones.	
BOARD DIRECTOR		2007 – 2013
Pharmeste	Pharma Company specialized in drug discovery, pain. Shareholders as main Investors: Zambon Group, MPS Ventures, MPH Ventures.	

SELL SIDE ADVISOR		2011 – 2013
Simple Agency	Simple Agency is a new generation digital marketing services provider that aims to simplify the approach to marketing and advertising in the interactive industry. Based on an innovative business model integrating marketing, media, creativity and technology, Simple Agency is focused on digital strategy, automated and real time display advertising, search and mobile marketing, attribution modelling and conversion funnel optimisation, creative production and web development.	
	July 30, 2013. Aegis Media (Dentsu Group) announced the acquisition of a majority stake in Simple Agency. Aegis Media is the world's leading focused media and digital communications specialist.	
ADVISORY BOARD MEMBER		2012 – 2013
Travellution, Paris, Incubateurs Nouveaux Medias	Travel Social Network. Investors: OSEO, a French quasi-governmental Agency, Business Angels.	
FOUNDER - INVESTMENT ADVISOR		2006 – 2012
Axòn Capital SGECR SA	Private Equity Company, closed-end funds active in EU, LatAm and India. Axòn Capital manages early to growth capital funds of over 130 Million USD in technology and innovation, supported by prestigious investors from all over the world. Axòn has a global footprint, with offices in Madrid, Miami, Bogotá and Bangalore (Associate office) and investors and clients in Europe, Latin America, the Middle East, Africa and India.	
BOARD DIRECTOR		2006 – 2012
GreenFluff	Green and Cleantech Company. Industrial shareholder: Boldrocchi Group.	
INDEPENDENT EXPERT OF THE EUROPEAN COMMISSION'S 7TH FRAMEWORK PROGRAM FOR RESEARCH		2010 – 2012
European Commission	Independent Expert for Evaluation of research grant proposals within the 7th Framework Program (FP7) for Research.	
FOUNDER AND CEO		2002 – 2011
Quantica SGR	Venture and Expansion Capital Company. The leading Italian VC firm (2002-2011) with about 100M€ under management. The first VC company specialized in investments stemming from the Italian scientific research. In 2008 Quantica was awarded by the "Private Equity of the Year – Premio Demattè" AIFI for the best early stage exit. EOS - Ethical Oncology Science and Banzai Group are part of the Principia I Fund portfolio.	
MENTOR		2011 – 2011
Start Up School - Augmendy	Start Up School	
BOARD DIRECTOR		2009 – 2010
OneDegree - Banzai Group	Smart Search Engine: yourank.it .com OneDegree is part of Banzai Group, Italian leader as Internet player, revenues around 100 million Euros; EPrice.it and SaldiPrivati.it are part of Banzai Group.	
BOARD DIRECTOR		2008 – 2008
NewCorTec Roma	Biomedical Company, Artificial Heart (V.A.D.)	

FOUNDER		1998 – 2004
Jobadvisor	Italian Career Book Leader (more than 100.000 copies), one of the first Italian e-recruiting website.	
COMMENTATOR		2001 – 2002
Il Sole 24 Ore	Commentator on Hi-tech and Biotech companies listed on Nasdaq and NYSE.	
CHIEF INVESTMENT MANAGER		1999 – 2002
Euroconsult SGR	Independent Asset Management Company, open-end funds, top performer in 1999 and 2000 as “Global Equity Fund” and as “Global Equity/Bond Fund”. In 2000, the Global Equity Fund was the top performer year on year of its category with more than 100% return.	
EQUITY ASSET MANAGER - PRIVATE BANKING		1999 – 1999
Albertini SIM	Private Banking boutique. As shareholder Societ� Generale then Dresdner Bank.	
PROPRIETARY TRADER AND ASSET MANAGER (OPTIONS AND BONDS)		1998 – 1998
Bayerische Landesbank	Leading German Bank, the Bank of the Bavarian Region. One of the three banks in EU with triple A by the top three international rating companies.	
EQUITY, BOND AND FUTURE PROPRIETARY TRADER		1997 – 1997
Banque Bruxelles Lambert	The second Belgian Bank, then part of ING Group, with branches also in Asia and USA.	



EDUCATION

UNIVERSITÀ CATTOLICA DEL SACRO CUORE		1992 - 1996
Laurea, Economia		